Contravisory Investment Management Inc. Purchases Shares of 10,147 Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Contravisory Investment Management acquired 10,147 Regeneron shares worth approximately $6.3 million during the second quarter. Institutional investors collectively own 83.31% of REGN.
• Regeneron reported quarterly earnings of $14.29 per share and revenue of $4.29 billion, exceeding analyst estimates, while revenue grew 16.7% year over year.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $797.75. The company also declared a quarterly dividend of $0.94 per share, although pending securities litigation presents a potential risk.

Contravisory Investment Management Inc. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 10,147 shares of the biopharmaceutical company's stock, valued at approximately $6,327,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of REGN. Allied Private Wealth LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $33,000. Jacobs & Co. CA boosted its holdings in Regeneron Pharmaceuticals by 0.9% in the second quarter. Jacobs & Co. CA now owns 10,372 shares of the biopharmaceutical company's stock valued at $6,467,000 after acquiring an additional 95 shares in the last quarter. Atwood & Palmer Inc. increased its position in Regeneron Pharmaceuticals by 1.5% during the 2nd quarter. Atwood & Palmer Inc. now owns 42,332 shares of the biopharmaceutical company's stock valued at $26,396,000 after purchasing an additional 630 shares during the period. Palouse Capital Management Inc. increased its position in Regeneron Pharmaceuticals by 6.2% during the 2nd quarter. Palouse Capital Management Inc. now owns 2,479 shares of the biopharmaceutical company's stock valued at $1,546,000 after purchasing an additional 145 shares during the period. Finally, Czech National Bank raised its holdings in Regeneron Pharmaceuticals by 3.6% in the 2nd quarter. Czech National Bank now owns 28,442 shares of the biopharmaceutical company's stock worth $17,735,000 after purchasing an additional 989 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $784.36 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The firm has a 50 day moving average price of $657.28 and a 200-day moving average price of $712.18. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $821.11. The firm has a market capitalization of $80.76 billion, a price-to-earnings ratio of 19.39, a PEG ratio of 1.33 and a beta of 0.21.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm's quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $12.81 EPS. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be given a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals's payout ratio is currently 9.29%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on REGN shares. Canaccord Genuity Group reduced their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a "buy" rating on the stock in a research report on Tuesday, May 19th. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a "hold" rating in a report on Wednesday, July 29th. Leerink Partners reaffirmed a "market perform" rating and set a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, May 18th. Barclays reduced their target price on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an "overweight" rating on the stock in a report on Thursday, April 30th. Finally, Wall Street Zen raised Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and ten have given a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $797.75.

Insider Activity

In related news, Director Arthur F. Ryan sold 200 shares of the company's stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by corporate insiders.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Barclays maintained its Buy rating on Regeneron. The reaffirmed bullish view provides support for REGN, particularly after the company’s recent earnings beat, which included revenue growth and earnings per share well above consensus. Barclays Keeps Their Buy Rating on Regeneron
• Neutral Sentiment: Intellia Therapeutics reported lower revenue because of reduced Regeneron collaboration revenue. Intellia’s second-quarter revenue declined 46.2%, but the item reflects Intellia’s financial results rather than a newly announced change in Regeneron’s pipeline or partnership strategy. NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
• Negative Sentiment: Several law firms reiterated notices about a pending securities class action against Regeneron. The lawsuit concerns alleged disclosure issues surrounding the failed Phase 3 melanoma trial, which reportedly led to a substantial market-value loss. Investors who purchased REGN shares during the August 1, 2025–May 15, 2026 class period have until September 14, 2026 to seek lead-plaintiff status. The repeated notices add legal and reputational risk but do not indicate a new lawsuit-related financial liability. Regeneron Class Action Lawsuit Deadline Notice

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source